FeesSafety
Pluang+

Invivyd reports Q3 2026 revenue growth and updates on COVID-19 antibody trials with imminent Phase 3 data.

Company Fundamentals
16 Nov 2026, 14:01 WIB
GlobeNewsWire
View Source
Bullish
Invivyd reports Q3 2026 revenue growth and updates on COVID-19 antibody trials with imminent Phase 3 data.

Invivyd announced an 18% increase in Q3 2026 revenue to $15.4 million, driven by demand for its COVID-19 monoclonal antibody PEMGARDA. The company updated timelines for Phase 3 trial data of VYD2311, a new COVID-19 antibody candidate, following discussions with the FDA on accelerated approval strategies. Positive Phase 3 LIBERTY trial results showed VYD2311's safety and tolerability surpassing mRNA vaccines, and a Phase 2 trial for Long COVID treatment has begun. Invivyd also appointed Marc Elia as CEO and plans a 2027 investor event to discuss commercial strategies for VYD2311.

Invivyd's Q3 2026 financial results and business updates provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 16, 2026 18:12 WIB: out of 150 priced US health stocks, 66 rose and 50 fell today. Notable movers include SMMT at USD 11.52 with a 1-day change of -18.59% and a typical hold time of 19 days, ABEO at USD 2.28 down 5.79% with a 22-day hold, and ENVB at USD 1.58 up 4.29% with a 16-day hold.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
21 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
21 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
21 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App